These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38271788)

  • 41. Polarization of tumor-associated macrophages by TLR7/8 conjugated radiosensitive peptide hydrogel for overcoming tumor radioresistance.
    Zhang Y; Feng Z; Liu J; Li H; Su Q; Zhang J; Huang P; Wang W; Liu J
    Bioact Mater; 2022 Oct; 16():359-371. PubMed ID: 35386314
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sono-Immunotherapy Mediated Controllable Composite Nano Fluorescent Probes Reprogram the Immune Microenvironment of Hepatocellular Carcinoma.
    Chen Y; Wu B; Shang H; Sun Y; Tian H; Yang H; Wang C; Wang X; Cheng W
    Int J Nanomedicine; 2023; 18():6059-6073. PubMed ID: 37908671
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Metabolism via Arginase or Nitric Oxide Synthase: Two Competing Arginine Pathways in Macrophages.
    Rath M; Müller I; Kropf P; Closs EI; Munder M
    Front Immunol; 2014; 5():532. PubMed ID: 25386178
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Supramolecular Nanotherapeutics for Macrophage Immunotherapy.
    Ramesh A; Brouillard A; Kulkarni A
    ACS Appl Bio Mater; 2021 Jun; 4(6):4653-4666. PubMed ID: 35007018
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Redirecting tumor-associated macrophages to become tumoricidal effectors as a novel strategy for cancer therapy.
    Zheng X; Turkowski K; Mora J; Brüne B; Seeger W; Weigert A; Savai R
    Oncotarget; 2017 Jul; 8(29):48436-48452. PubMed ID: 28467800
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Chimeric Peptide Engineered Bioregulator for Metastatic Tumor Immunotherapy through Macrophage Polarization and Phagocytosis Restoration.
    Chen XY; Yan MY; Liu Q; Yu BX; Cen Y; Li SY
    ACS Nano; 2023 Aug; 17(16):16056-16068. PubMed ID: 37578051
    [TBL] [Abstract][Full Text] [Related]  

  • 47. TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy.
    Rodell CB; Arlauckas SP; Cuccarese MF; Garris CS; Li R; Ahmed MS; Kohler RH; Pittet MJ; Weissleder R
    Nat Biomed Eng; 2018 Aug; 2(8):578-588. PubMed ID: 31015631
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy.
    Cao Y; Qiao B; Chen Q; Xie Z; Dou X; Xu L; Ran H; Zhang L; Wang Z
    Acta Biomater; 2023 Apr; 160():239-251. PubMed ID: 36774974
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reprogramming Hypoxic Tumor-Associated Macrophages by Nanoglycoclusters for Boosted Cancer Immunotherapy.
    Zhao YD; An HW; Mamuti M; Zeng XZ; Zheng R; Yang J; Zhou W; Liang Y; Qin G; Hou DY; Liu X; Wang H; Zhao Y; Fang X
    Adv Mater; 2023 Jun; 35(24):e2211332. PubMed ID: 36971342
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Repolarizing tumor-associated macrophages by layered double hydroxide-based deacidification agent for tumor chemodynamic therapy and immunotherapy.
    Chen C; Zhang W; Lu SY; Wang J; Tan Y; Zhao S; Ouyang Y; Xu L; Zhou B; Yin X; Ran H; Liu H
    Colloids Surf B Biointerfaces; 2023 Mar; 223():113157. PubMed ID: 36716658
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oceanimonas sp. BPMS22-derived protein protease inhibitor induces anti-leishmanial immune responses through macrophage M2 to M1 repolarization.
    Jayaraman A; Srinivasan S; Kar A; Harish BS; Charan Raja MR; Uppuluri KB; Kar Mahapatra S
    Int Immunopharmacol; 2022 Nov; 112():109281. PubMed ID: 36183681
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cationic polysaccharide spermine-pullulan drives tumor associated macrophage towards M1 phenotype to inhibit tumor progression.
    Xie L; Yang Y; Meng J; Wen T; Liu J; Xu H
    Int J Biol Macromol; 2019 Feb; 123():1012-1019. PubMed ID: 30439425
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Repolarizing Tumor-Associated Macrophages and inducing immunogenic cell Death: A targeted liposomal strategy to boost cancer immunotherapy.
    Li C; Wang L; Li Z; Li Z; Zhang K; Cao L; Wang Z; Shen C; Chen L
    Int J Pharm; 2024 Feb; 651():123729. PubMed ID: 38142016
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nitric oxide prevents aortic neointimal hyperplasia by controlling macrophage polarization.
    Lavin B; Gómez M; Pello OM; Castejon B; Piedras MJ; Saura M; Zaragoza C
    Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1739-46. PubMed ID: 24925976
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Magnetic Resonance Imaging Nanoprobe Quantifies Nitric Oxide for Evaluating M1/M2 Macrophage Polarization and Prognosis of Cancer Treatments.
    Liu X; Wang M; Jiang Y; Zhang X; Shi C; Zeng F; Qin Y; Ye J; Hu J; Zhou Z
    ACS Nano; 2023 Dec; 17(24):24854-24866. PubMed ID: 38047965
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Curcumin Reprograms TAMs from a Protumor Phenotype towards an Antitumor Phenotype via Inhibiting MAO-A/STAT6 Pathway.
    Jiang M; Qi Y; Huang W; Lin Y; Li B
    Cells; 2022 Nov; 11(21):. PubMed ID: 36359867
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells.
    Xu HZ; Li TF; Wang C; Ma Y; Liu Y; Zheng MY; Liu ZJ; Chen JB; Li K; Sun SK; Komatsu N; Xu YH; Zhao L; Chen X
    J Nanobiotechnology; 2021 Sep; 19(1):268. PubMed ID: 34488792
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dual Inhibition of Endoplasmic Reticulum Stress and Oxidation Stress Manipulates the Polarization of Macrophages under Hypoxia to Sensitize Immunotherapy.
    Jiang M; Li X; Zhang J; Lu Y; Shi Y; Zhu C; Liu Y; Qin B; Luo Z; Du Y; Luo L; Peng L; You J
    ACS Nano; 2021 Sep; 15(9):14522-14534. PubMed ID: 34414762
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Nitric Oxide (NO) Nanoreporter for Noninvasive Real-Time Imaging of Macrophage Immunotherapy.
    Ramesh A; Kumar S; Brouillard A; Nandi D; Kulkarni A
    Adv Mater; 2020 Jun; 32(24):e2000648. PubMed ID: 32390270
    [TBL] [Abstract][Full Text] [Related]  

  • 60. TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages.
    Liu Z; Xie Y; Xiong Y; Liu S; Qiu C; Zhu Z; Mao H; Yu M; Wang X
    Cancer Lett; 2020 Jan; 469():173-185. PubMed ID: 31629935
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.